Inflammatory biomarkers in Alzheimer’s disease plasma
Full item page Simple item page
- dc.contributor.author Morgan, Angharad R.
- dc.contributor.author Molinuevo, José Luis
- dc.contributor.author Morgan, B. Paul
- dc.date.accessioned 2023-01-23T07:23:43Z
- dc.date.available 2023-01-23T07:23:43Z
- dc.date.issued 2019
- dc.description.abstract Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
- dc.format.mimetype application/pdf
- dc.identifier.citation Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium, et al. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimers Dement. 2019 Jun;15(6):776-87. DOI: 10.1016/j.jalz.2019.03.007
- dc.identifier.doi http://dx.doi.org/10.1016/j.jalz.2019.03.007
- dc.identifier.issn 1552-5260
- dc.identifier.uri http://hdl.handle.net/10230/55363
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Alzheimer's & Dementia: the Journal of the Alzheimer's Association. 2019 Jun;15(6):776-87
- dc.rights Copyright © 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Alzheimer's disease
- dc.subject.keyword Biomarker
- dc.subject.keyword Complement
- dc.subject.keyword Inflammation
- dc.subject.keyword Plasma
- dc.title Inflammatory biomarkers in Alzheimer’s disease plasma
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion